Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic Efficacy Study of artemether-lumefantrine and dihydroartemisinin-piperaquine in children with uncomplicated falciparum malaria
PACTR202607738028407Not yet recruiting
- Sponsor
- PATH
- Start
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of artemether + lumefantrine and dihydroartemisinin + piperaquine in Malaria (2 arms), sponsored by PATH. Primary endpoints: Therapeutic efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine and Clinical and parasitological efficacy classification. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
artemether + lumefantrinedihydroartemisinin + piperaquine
03
Conditions
Malaria
Beyond the preview
Go deeper on PACTR202607738028407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202607738028407.